Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|December 1, 2016

BioPharm International

  • BioPharm International-12-01-2016
  • Volume 29
  • Issue 12

Chromatograph Enables Fast Recovery of Target Compounds

The Prominence Ultra-Fast Preparative and Purification Liquid Chromatograph (UFPLC) from Shimadzu enables fast recovery of highly purified target compounds from complex samples including organic synthesis reaction mixtures and natural products.

The Prominence Ultra-Fast Preparative and Purification Liquid Chromatograph (UFPLC) from Shimadzu enables fast recovery of highly purified target compounds from complex samples including organic synthesis reaction mixtures and natural products. The Prominence UFPLC offers a single automated workflow that uses on-line fraction trapping as an alternative to traditional fraction collection, allowing elution of collected compounds in highly volatile organic solvents that can be easily evaporated, resulting in ultra-high-weight purity compounds in approximately 90 minutes. 

The Prominence UFPLC integrates traditional Prep LC with novel fraction trapping for up to five compounds of interest. Shimadzu’s Shim-pack C2P-H trapping column retains target compounds, allowing unwanted organic solvents, water, and additives to be flushed away. The Prominence UFPLC integrates Prep LC, fraction trapping, processing, and recovery into a single instrument and occupies approximately one-third of the bench space of conventional configurations. 

Shimadzu


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.